Gene Linked to Millions Affected by Disorders
Groundbreaking Gene Finding Offers New Hope for Demyelinating Diseases
Table of Contents
Scientists Uncover Key Regulator of Myelin Formation, Paving the Way for Novel Treatments
Portland, OR – Researchers at Oregon Health & Science University (OHSU) have identified a crucial gene that plays a significant role in the formation of myelin, the protective sheath essential for rapid nerve cell interaction. this discovery opens a promising new avenue for understanding and potentially treating a range of debilitating demyelinating diseases, including leukodystrophies and multiple sclerosis (MS).
Unraveling the Mystery of Myelin
Myelin acts as an insulator for nerve fibers, enabling swift and efficient transmission of electrical signals throughout the nervous system. Damage to this vital coating, known as demyelination, disrupts these signals, leading to severe neurological impairments. While demyelination in infants can manifest as leukodystrophies like HLD19, similar pathological processes are at the heart of multiple sclerosis, a chronic autoimmune disease affecting over 2.8 million people globally.
“This gives us a brand-new angle for understanding and potentially treating demyelinating diseases,” stated Dr. Murali Murthy, a lead researcher on the project.
A Conserved Mechanism Across Species
The OHSU team’s research has demonstrated that the newly identified gene’s influence on myelin is not only scientifically validated but also conserved across different species. Studies in zebrafish and mice have confirmed its critical function.
“We’ve shown that this gene’s effect on myelin is not only real – it’s conserved across species, including zebrafish and mice,” Murthy explained. “That gives us powerful models to further study the disease and screen potential drug therapies.” This cross-species validation is a significant step, providing robust preclinical models for future research and therapeutic development.
Future Directions: Targeting Myelin Formation
The research team is now focused on delving deeper into the intricate mechanisms by which this gene regulates the complex cellular machinery responsible for myelin formation. A key objective is to identify other proteins that may collaborate with this gene, assisting myelinating cells in sensing their physical habitat within the brain.
“We’re at the beginning of a new research direction,” Murthy added. “We want to understand the exact steps in myelin formation where this gene plays a role – and whether that process can be targeted with drugs. If so, it could reshape how we treat both rare leukodystrophies and more common conditions like MS.”
The potential to develop targeted drug therapies that can either promote myelin repair or prevent its degradation holds immense promise for patients suffering from these challenging neurological conditions.
A Collaborative Triumph
This significant breakthrough is the culmination of a unique and highly collaborative effort involving the Murthy, Monk, and Emery labs at OHSU. The project leveraged diverse expertise spanning molecular biology, genetics, model organisms, and physiology, underscoring the power of interdisciplinary research.
“This kind of work is only possible in a highly collaborative environment like OHSU,” Murthy emphasized.”Our team brought together different perspectives to tackle a challenging and meaningful problem. it’s incredibly exciting to think about the long-term impact this could have on patients.”
OHSU Research Team
In addition to Murthy, Monk, and Emery, the OHSU co-authors contributing to this groundbreaking study include: Julia Halford, ph.D.; Amanda Senator, MS; Sage Berryman, BS; Antonio Muñoz, BS; Destinee Semidey, BA; Ryan Doan, Ph.D.; Adam Coombs, BS; Katie Emberley, BS; and Brandon Noimany.
Funding and Ethical Oversight
This research was generously supported by the McKnight Endowment Fund for Neuroscience, the OHSU Silver Family Foundation, The Laura Fund, and the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health under award number R01NS120651. The content presented reflects the sole responsibility of the authors and does not necessarily represent the official views of the NIH or other funding bodies.
All research involving animal subjects at OHSU undergoes rigorous review and approval by the university’s Institutional Animal Care and Use Committee (IACUC). The IACUC prioritizes the health and safety of animal research subjects and personnel, ensuring all proposed research demonstrates scientific value and justifies the use of live animals.